AnaptysBio, Inc.
ANAB
$64.72
$0.000.00%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 234.60M | 169.47M | 123.16M | 111.87M | 91.28M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 234.60M | 169.47M | 123.16M | 111.87M | 91.28M |
| Cost of Revenue | 135.97M | 153.00M | 163.81M | 167.98M | 163.84M |
| Gross Profit | 98.63M | 16.47M | -40.64M | -56.11M | -72.56M |
| SG&A Expenses | 50.74M | 45.14M | 45.50M | 44.18M | 42.39M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 186.71M | 198.14M | 209.30M | 212.16M | 206.23M |
| Operating Income | 47.90M | -28.68M | -86.14M | -100.29M | -114.95M |
| Income Before Tax | -13.07M | -84.55M | -132.52M | -140.58M | -145.23M |
| Income Tax Expenses | 164.00K | 77.00K | 77.00K | 47.00K | 3.00K |
| Earnings from Continuing Operations | -13.23 | -84.63 | -132.59 | -140.62 | -145.23 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.23M | -84.63M | -132.59M | -140.62M | -145.23M |
| EBIT | 47.90M | -28.68M | -86.14M | -100.29M | -114.95M |
| EBITDA | 48.46M | -28.10M | -85.56M | -99.70M | -114.34M |
| EPS Basic | -0.30 | -2.80 | -4.48 | -4.84 | -5.20 |
| Normalized Basic EPS | -0.18 | -1.75 | -2.80 | -3.02 | -3.25 |
| EPS Diluted | -0.52 | -2.82 | -4.48 | -4.84 | -5.20 |
| Normalized Diluted EPS | -0.32 | -1.76 | -2.80 | -3.02 | -3.25 |
| Average Basic Shares Outstanding | 87.29M | 117.74M | 118.80M | 117.34M | 113.50M |
| Average Diluted Shares Outstanding | 117.49M | 118.92M | 118.80M | 117.34M | 113.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |